Myelodysplastic Syndrome Clinical Trial
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Summary
RATIONALE: Gathering information about quality of life, fatigue, and other symptoms from patients with myelodysplastic syndromes may help doctors learn more about the disease and may help plan treatment.
PURPOSE: This clinical trial is studying quality of life and symptoms in patients with newly diagnosed myelodysplastic syndromes.
Full Description
This study will ultimately aim at providing the scientific community with additional patient-reported health status data to support and further facilitate the clinical decision-making process. This project has thus a number of goals. The main objective of the protocol is to improve our understanding of the possible added prognostic value of patients' judgment on their own health status and its potential clinical implications. This would aim at providing clinicians with an easy and brief to administer patient-reported health status scale or tool to be used to make more informed treatment decisions. In addition, along with other recent evidence (also looking at the prognostic value of patients' health status judgment in MDS patients), the data of this research could possibly serve to devise a patient-based prognostic index to be used in this higher risk population.
Eligibility Criteria
Inclusion criteria
Patients with newly diagnosed myelodysplastic syndrome (MDS) according to WHO classification with any known IPSS risk score category. The initial diagnosis of MDS is acceptable within 3 months before date of registration.
Having a full baseline QoL Evaluation completed (i.e. EORTC QLQ-C30; EQ5D; FACIT-Fatigue and Control Preference Scale).
Adult patients (≥ 18 years old).
Written informed consent provided.
Exclusion criteria
Patients who have received prior treatment other than platelets or RBC transfusions, iron chelation, antibiotic/virostatic drugs, vitamins;
Patients with therapy related MDS.
Having any kind of psychiatric disorder or major cognitive dysfunction.
Not able to read and understand local language.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
New York New York, 10065, United States
Houston Texas, 77030, United States
Innsbruck , , Austria
Antwerpen , , Belgium
Brugge , , Belgium
Bruxelles , , Belgium
Liege , , Belgium
Curitiba , , Brazil
China , , China
Kunming , , China
Rijeka , , Croatia
Prague , , Czechia
Saint-Cloud , , France
Toulouse , , France
Dresden , , Germany
Freiburg , , Germany
San Giovanni Rotondo Foggia, 71013, Italy
Ivrea Torino, 10015, Italy
Asti , , Italy
Bari , 70010, Italy
Cagliari , , Italy
Cagliari , , Italy
Catania , , Italy
Catanzaro , , Italy
Cona , , Italy
Firenze , , Italy
Genova , 16132, Italy
Latina , , Italy
Lecce , 73100, Italy
Meldola , , Italy
Milano , 20132, Italy
Milano , 20162, Italy
Modena , , Italy
Monza , , Italy
Novara , 28100, Italy
Orbassano , , Italy
Parma , , Italy
Pavia , 27100, Italy
Piacenza , , Italy
Reggio Emilia , , Italy
Roma , 00128, Italy
Roma , 00133, Italy
Roma , 00161, Italy
Roma , 00168, Italy
Roma , 00184, Italy
Rome , , Italy
Rovigo , 45100, Italy
Sassari , , Italy
Torino , , Italy
Taipei , , Taiwan
Bradford , , United Kingdom
Leeds , , United Kingdom
London , , United Kingdom
How clear is this clinincal trial information?